Publications
Publications
Show Results For
- All HBS Web
(2,338)
- Faculty Publications (849)
- 2025
- Working Paper
Antitrust Platform Regulation and Entrepreneurship: Evidence from China
By: Ke Rong, D. Daniel Sokol, Di Zhou and Feng Zhu
Many jurisdictions have launched antitrust enforcement and brought in regulation of large tech platforms. The swift and strict implementation of China’s Anti-Monopoly Guidelines for the Platform Economy (Platform Guidelines) provides a quasi-natural experiment... View Details
- January 11, 2024
- Article
Understanding the Tradeoffs of the Amazon Antitrust Case
By: Chiara Farronato, Andrey Fradkin, Andrei Hagiu and Dionne Lomax
Regulators in the United States and Europe have been taking on Big Tech, challenging what they say are the companies’ anti-competitive and predatory strategies that harm consumers and third-party users of their platforms. This article examines the FTC’s case against... View Details
- January 2024 (Revised January 2025)
- Case
Colbún and Chile's Energy Transition
By: Forest Reinhardt, Jenyfeer Martinez Buitrago and Mariana Cal
In May 2023, Colbún, Chile’s second-largest electricity generator, plans capacity expansions using renewable energy and storage. This strategy supports Chile’s commitment to carbon neutrality (also known as net zero emissions) by 2050. The case delves into the... View Details
- 2024
- Article
Technological Adoption and Taxation: The Case of China's Golden Tax Reform
By: Haichao Fan, Yu Liu, Nancy Qian and Jaya Y. Wen
This paper investigates the effect of Phase 2 of the Golden Tax Project on VAT in China. The reform introduced computer-generated invoices and electronic transaction linking. Using a difference-in-differences strategy, we show that the reform increased VAT by reducing... View Details
- December 2023
- Case
The American Bully XL
By: Robin Greenwood, Richard S. Ruback, Johnathan Sun and Robert Ialenti
The American Bully XL, first introduced to the United Kingdom around 2014, had been held responsible for a disproportionate share of both dog-related attacks and deaths. The case discusses the announcement, in October 2023, that the dog breed would be added to a list... View Details
- December 2023 (Revised May 2024)
- Case
Building Resiliency in McDonald's Supply Chain
By: David E. Bell, Damien McLoughlin and David Lane
Considers McDonald’s efforts to build resilience into its global supply chain so that the company and its suppliers can better navigate the increasing pressures and pace of climate change and regulatory change, including a focus on supplying sustainable beef, while the... View Details
- December 2023 (Revised August 2024)
- Case
Monsters in the Machine? Tackling the Challenge of Responsible AI
By: Paul M. Healy and Debora L. Spar
In November of 2022, the small tech company OpenAI released ChatGPT, an artificial intelligence chatbot which quickly captured the public’s imagination—becoming the world’s fastest-growing consumer application within months of its release. Though observers from across... View Details
- November–December 2023
- Article
Tax-Loss Harvesting with Cryptocurrencies
By: Lin William Cong, Wayne Landsman, Edward Maydew and Daniel Rabetti
We describe the taxation landscape in the cryptocurrency markets, especially concerning U.S. taxpayers, and examine how recent increases in tax scrutiny have led to changes in crypto investors' trading behavior. We argue conceptually and then empirically document that... View Details
- November 2023 (Revised March 2024)
- Technical Note
Customer Data Privacy
By: Eva Ascarza and Ta-Wei Huang
This note provides an overview of the evolving landscape of customer data privacy in 2023. It highlights two pivotal aspects that make privacy a central concern for businesses: building and maintaining customer trust and navigating the intricate regulatory... View Details
- November 2023
- Case
Will Fintechs and Central Banks Play in Emtech's Sandbox?
By: Daniel Isenberg and William R. Kerr
In February 2023, Emtech’s founder Carmelle Cadet is facing a dilemma. Rapidly running out of cash, Cadet has a term sheet from a leading VC but has a choice of how to structure the investment. The decision will have significant implications for Cadet’s own stake, as... View Details
- November 2023
- Case
Tata Group in 2021: Pursuing Profits through Purpose
By: Tarun Khanna, Krishna G. Palepu and Vidhya Muthuram
October 8, 2021: Tata Sons won a bid to acquire India’s national carrier Air India, marking the airline's return to its original owners after 68 long years. The winning bid of $2.4 billion gave Tata Sons full ownership of the airline and its coveted network of 6,200... View Details
- 2023
- Working Paper
The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina
By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed... View Details
- October 2023 (Revised May 2024)
- Case
JSW Steel: Balancing Growth While Decarbonizing
By: Vikram S Gandhi and Radhika Kak
Sajjan Jindal, Chairman & Managing Director of JSW Steel, India's largest steel producer by market capitalization, was facing a dilemma. Steel demand in India was expected to grow exponentially over the next decade. However, given its traditional reliance on carbon,... View Details
- September 2023
- Case
The Rise and Fall of FTX
In November 2022, Sam Bankman-Fried's multi-billion-dollar crypto exchange, FTX, collapsed, wiping out investors and throwing the crypto industry into disarray. As FTX's founder and CEO, Bankman-Fried developed a reputation for his unerring business sense and... View Details
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
- 2023
- Working Paper
Much Ado About Nothing? Overreaction to Random Regulatory Audits
By: Samuel Antill and Joseph Kalmenovitz
Regulators often audit firms to detect non-compliance. Exploiting a natural experiment in the lobbying industry, we show that firms overreact to audits and this response distorts prices and reduces welfare. Each year, federal regulators audit a random sample of... View Details
- 2023
- Article
Towards Bridging the Gaps between the Right to Explanation and the Right to Be Forgotten
By: Himabindu Lakkaraju, Satyapriya Krishna and Jiaqi Ma
The Right to Explanation and the Right to be Forgotten are two important principles outlined to regulate algorithmic decision making and data usage in real-world applications. While the right to explanation allows individuals to request an actionable explanation for an... View Details
- July 2023
- Article
So, Who Likes You? Evidence from a Randomized Field Experiment
By: Ravi Bapna, Edward McFowland III, Probal Mojumder, Jui Ramaprasad and Akhmed Umyarov
With one-third of marriages in the United States beginning online, online dating platforms have become important curators of the modern social fabric. Prior work on online dating has elicited two critical frictions in the heterosexual dating market. Women, governed by... View Details
- 2023
- Book
The State and Capitalism in China
By: Meg Rithmire, Margaret M. Pearson and Kellee S. Tsai
This element explains China's political economic evolution from state socialist economy to a reform era state capitalism model to a more politicized, risk management approach we call "party-state capitalism." We emphasize the internal and external sources of perceived... View Details
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details